D. E. Shaw & Co., Inc. Ibere Pharmaceuticals Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 14, 2023	SELL	$9.93 - $10.09 $1.24 Million - $1.26 Million	-125,008 Reduced 45.46%	150,000 $1.51 Million
Q3 2022 Nov 14, 2022	BUY	$0.11 - $9.94 $11 - $994	100 Added 0.04%	275,008 $2.73 Million
Q2 2022 Aug 15, 2022	BUY	$9.77 - $9.84 $996,012 - $1 Million	101,946 Added 58.94%	274,908 $2.7 Million
Q1 2022 May 16, 2022	SELL	$9.69 - $9.81 $2.24 Million - $2.27 Million	-231,214 Reduced 57.21%	172,962 $1.7 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $9.77 $2.35 Million - $2.37 Million	242,637 Added 150.2%	404,176 $3.93 Million
Q3 2021 Nov 15, 2021	BUY	$9.61 - $9.78 $1.31 Million - $1.34 Million	136,539 Added 546.16%	161,539 $1.57 Million
Q2 2021 Aug 16, 2021	BUY	$9.65 - $9.95 $241,250 - $248,749	25,000 New	25,000 $242,000

Others Institutions Holding IBER

# of Institutions

1

Shares Held

0

Call Options Held

0

Put Options Held

0

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About IBERE PHARMACEUTICALS

Ticker IBER
Exchange NYSE
Sector Financial Services
Industry Shell Companies
Shares Outstandng 13,800,000
Description
Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.

More about IBER

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.